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Abstract
Background: Astragaloside IV (ASI) in Radix Astragali is believed to be the active component in
treating heart failure. The present study aims to examine the effects of ASI on cardiovascular
parameters in long-term heart failure in rats.
Methods: Using echocardiographic and haemodynamic measurements, we studied the effects of
ASI on congestive heart failure (CHF) induced by ligation of the left coronary artery in rats.
Results: ASI (0.1, 0.3 and 1.0 mg/kg/day) attenuated the decline of fractional shortening (FS). The
peak derivatives of the left ventricle (LV) pressure (dp/dt) in ASI-treated groups significantly
increased. Both LV internal diameters in diastole (LVIDd) and in systole (LVIDs) decreased
significantly after ASI treatment (0.3 and 1.0 mg/kg/day). ASI (1.0 mg/kg/day) attenuated the
decrease of LV systolic pressure (LVSP). ASI treatment inhibited compensatory hypertrophy of
myocardial cells and lowered the number of apoptotic myocytes.
Conclusion: ASI improved cardiac functions as measured by cardiovascular parameters.
Background
Heart failure is a major cause of morbidity and mortality
around the world and remains a serious outcome of myo-
cardial infarction (MI). Radix Astragali (Huangqi) is a Chi-
nese herbal medicine reported to improve the left
ventricular function and mitigating the cardiac hypertro-
phy in heart failure patients [1-5]. Recently, increasing evi-
dence shows that Astragaloside IV (ASI), which is a
saponin, is the active ingredient in the treatment of heart
failure [6-10]. ASI increased systolic and diastolic func-
tions in acute heart failure of canine induced by pentobar-
bital sodium and improved the cardiac depressant effect
induced by propanolol. Another study [11] further dem-
onstrated a protective effect on the left ventricular model-
ling and ejection function in patients with congestive
heart failure (CHF) after a two-week continuous adminis-
tration of ASI. Furthermore, the antiapoptotic activities of
ASI were discovered in some diseases such as myocarditis
[12].
Recent studies showed that cardiac hypertrophy and
apoptosis were correlated with the severity of CHF
[13,14]. Cardiocyte apoptosis plays an important role in
the remodelling process and in the transition from adap-
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tive myocardial condition to end-stage cardiac failure.
Cardiac apoptosis is a genetically programmed process
executed by caspases, a family of ubiquitous cysteine pro-
teases. Caspases are present in the cell as inactive pro-cas-
pases, which are activated in response to apoptotic stimuli
including myocardial pathological conditions (e.g.
hypoxia, oxidation, and mechanical load), cytokines (e.g.
TNF-α, IL-6 and ITF) and neuroendocrine factors (e.g.
angiotensin II and NO) [15]. Gene families Bcl-2 and P53
also take part in the regulation of apoptosis [16]. How-
ever, the effects of ASI on heart failure have not been
extensively elucidated.
The present study aims to examine the effects of ASI on
cardiovascular parameters in long-term heart failure as an
outcome of MI in rats.
Methods
Animals and reagents
Wistar rats weighting 228.3 ± 13.0 g (203–272 g) were
housed at 22 ± 2°C in a temperature-regulated room
equipped with an automatic 12:12 hour photoperiod and
were provided with food and water. ASI is colourless nee-
dles crystallized from Astragaloside by ethyl acetate-etha-
nol, melting point 295–300°C, purity>95%. ASI was
dissolved in 20% dimethylsulfoxide (<0.05%) and
diluted with normal saline (NS) when studied in vivo.
Quinapril was supplied by the Shanghai Institute of Phar-
maceutical Industry (certificate no.051).
Induction of MI and medications
MI in Wistar rats was induced by coronary ligation.
Through a thoracotomy on the left side, the heart was
exteriorized and extensive MI was induced by ligation of
the left coronary artery according to Tonnessen et al. [17].
Animals in the sham group were subjected to the same
surgical procedure, except that the coronary artery was not
ligated. Echocardiography was performed three weeks
later in the surviving rats anaesthetized by ether; those
with heart failure according to echocardiographic criteria
were randomly divided into five groups [18,19] where
each group had ten animals. Group one (model) received
NS; group two to four received ASI at 0.1, 0.5, 1.0 mg/kg
respectively; group five received quinapril at 1.0 mg/kg.
The animals in the sham group received NS. The treat-
ment, which started three weeks after coronary ligation,
was carried out via intravenous injection once a day for 14
days. The experiment lasted for five weeks.
Echocardiography
We used a commercially available echocardiography
(VIVID 3 Pro, GE, USA) equipped with a 10 MHz linear
transducer. The animals, with shaved chests, were placed
in supine position. The transducer was placed gently on
the left. Two-dimensional (2D) images of the left ventricle
(LV) were obtained in both parasternal long-axis and
short-axis views at a frame rate of 130 Hz. M-mode trac-
ings were recorded at the level of the papillary muscles
with 2D guidance. LV wall thickness and cavity diameters
were measured outside the infarcted area by M-mode,
through the largest diameters of the ventricle. Each image
consisted of 24 consecutive heart cycles and the focus area
was 0–40 mm from the transducer. Fractional shortening
(FS), in percentage, was calculated according to the fol-
lowing formula:
where LVIDd is the LV internal diameter in diastole, and
LVIDs is the LV internal diameter in systole [20]. LV inter-
nal diameters were measured according to the guidelines
of the American Society of Echocardiography [21]. All
measurements were obtained on at least three beats. LV
systolic wall stress = 1.36 × (aortic systolic pressure ×
LVIDs)/(IVSs + LVPWs), where IVSs is the interventricular
septum thickness at end-systole and LVPWs is the poste-
rior wall thickness at end-systole. The tracings were ana-
lyzed by one author (WTW) who had no prior knowledge
of the group assignment.
Haemodynamic measurements
An F-2 (0.7 mm in internal diameter) catheter with pres-
sure-transducer was inserted through the right carotid
artery into the aorta to determine the mean arterial blood
pressure. The catheter was subsequently advanced further
into the LV, and end-diastolic pressure (LVEDP) and
systolic pressure (LVSP) were recorded. The transducer
was connected to a polygraph (model 6300, Nihon Koh-
den, Japan) and a data acquisition workstation (model
MP150, BIOPAC Systems, USA) to a computer running
Acknowledge (version 3.7.1). LVEDP was read directly
from the pressure curve as being the diastolic pressure
immediately preceding the pressure rise associated with
LV contraction. Peak positive and peak negative first deriv-
atives of the LV pressure (+LVdp/dt and -LVdp/dt) were
calculated with the Acknowledge software.
Tissue sampling
After haemodynamic measurements, the rats were subse-
quently euthanized by excision of the heart. The atria and
ventricles were sectioned, separated and weighted. The
infarcted area (scar tissue) was excised with care from the
non-infarcted LV to avoid contamination of viable myo-
cardial tissue by necrotic tissue. The infarction size was
estimated by weighing the excised scar tissue. The non-inf-
arcted LV from the CHF rats was further sectioned by sep-
arating the tissue contiguous to the infarcted area (viable
LV free wall) and the tissue distal to the infarcted area
(interventricular septum). A piece of the apical part of the
nonischemic interventricular septum was processed sepa-
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rately for histochemical analysis of apoptosis. The right
tibia of each rat was isolated and its length measured [22].
Myocardial tissue from interventricular septum was
microtomed into 5 μm sections. Apoptotic cell death was
analyzed by terminal-deoxynucleotidyl transferase (TdT)-
mediated dUTP-digoxigenin nick end labelling (TUNEL)
method. The Bcl-2 associated X protein (Bax) related to
apoptosis was determined with biotin SP-HRP.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
The statistical significance between groups was evaluated
by a one-way analysis of variance (ANOVA) with SAS soft-
ware (version 10.0, SAS Institute, USA). P values < 0.05
are considered to be statistically significant.
Results
Effects of ASI on the LV functions
Three weeks after coronary artery ligation, the FS of the
animals in the model group markedly decreased and fur-
ther decreased after the animals were given NS for two
more weeks. The values of +dp/dt and -dp/dt decreased
36% and 48% respectively two weeks after NS administra-
tion. One week after the administration of ASI (0.1, 0.3
and 1.0 mg/kg/day), the decline of the FS was attenuated
(P < 0.05, P < 0.001 and P < -0.001). Two weeks after the
administration of ASI (at a dose of 1.0 mg/kg/day), the
decline of the FS was attenuated (P < 0.05). The dp/dt in
the ASI-treated groups (0.3 and 1.0 mg/kg/day) signifi-
cantly increased compared with the model group (P  <
0.05 and P < 0.01) (Tables 1 and 2).
Effects of ASI on LV dimensions
LV geometry in various groups was analyzed with echocar-
diography (Table 3). The findings demonstrated the pro-
gression of LV remodelling during a 5-week period after
coronary artery ligation in the absence of treatment. Both
LVIDd and LVIDs increased significantly and progres-
sively three weeks after surgery. Both LVIDd and LVIDs
decreased significantly two weeks after ASI treatment (0.3
and 1.0 mg/kg/day).
Effects of ASI on haemodynamics
LVSP in the model group was 21% lower than that in the
sham group, while LVEDP in the model group increased
markedly, suggesting severe cardiac dysfunction in the
CHF rats after coronary artery ligation (Table 4). ASI (at
doses of 0.1 and 0.3 mg/kg/day) attenuated the decrease
of LVSP, while LVEDP decreased 55.4% (P < 0.01) com-
pared with the model group. The rats in the model group
displayed higher wall stress of LV. ASI (1.0 mg/kg/day)
significantly lowered the wall stress by 22% (P < 0.05)
compared with the model group.
Effects of ASI on myocardial hypertrophy
LA, LV, RA and RV weight-to-tibial-length ratios decreased
significantly after ASI (1.0 mg/kg/day) treatment com-
pared with the model group (Table 5).
Effects of ASI on myocardial apoptosis and Bax
Assessment of apoptotic cell death was performed with in
situ TUNEL staining of mycardial sections. Apoptosis was
observed in the CHF rats with an increased level of Bax
protein. Compared with the model group, both apoptotic
cells and Bax proteins were reduced markedly after two
weeks of ASI treatment (1.0 mg/kg/day) (Table 6).
Discussion
CHF is a serious outcome of MI. Many rats may die from
serious ischemia after induction of acute MI by coronary
artery ligation. However, rats suffering from slight
ischemia may develop CHF. In the present study, surgery
was performed on 141 rats, among which 48 rats died
within 24 hours (34% mortality rate) and 61 rats devel-
oped CHF according to echocardiographic criteria for
CHF [22]. The rats were dissected for the scar tissue at the
end of experiments. Rats with coronary artery ligation had
moderate infarcted area of 2.67 ± 0.39 (2.08–3.52) mg/
mm. Rats in the sham group had no infarcted area.
Routinely used on humans, echocardiography is emerging
as a noninvasive method for evaluating global systolic car-
diac function and LV dimensions in rats [23-27]. In the
Table 1: Effects of ASI on FS (%)
After treatment
Group Dose (mg/kg/day) Normal Before treatment 1 week 2 weeks
Sham - 73.0 ± 5.7 68.8 ± 6.5 70.9 ± 3.4 66.1 ± 8.0
Model - 68.8 ± 10.1 (0.2193) 30.8 ± 5.0+++ 26.1 ± 6.6+++ 22.7 ± 7.6+++
ASI 0.1 72.8 ± 3.6 (0.2417) 28.9 ± 4.6 (0.4213) 34.2 ± 7.5* (0.0163) 27.4 ± 7.8 (0.2620)
ASI 0.3 72.1 ± 9.6 (0.3329) 28.8 ± 6.9 (0.3973) 41.5 ± 11.3*** 28.8 ± 8.9 (0.1474)
ASI 1.0 68.4 ± 6.7 (0.9061) 31.7 ± 2.5 (0.7024) 42.9 ± 7.7*** 35.8 ± 13.2** (0.0028)
Quinapril 1.0 70.1 ± 7.5 (0.7016) 30.2 ± 4.7 (0.7989) 42.4 ± 4.7*** 31.4 ± 8.8* (0.0411)
Note: Values are mean ± SD in each group (n = 10). +++P < 0.001: statistical significance over the sham group (comparison of group means after 
ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001: statistical significances over the model group (comparison of group means after ANOVA). No 
statistical significance between ASI (1.0 mg/kg/day) and Quinapril treatments. Exact P values are available in brackets.Chinese Medicine 2009, 4:6 http://www.cmjournal.org/content/4/1/6
Page 4 of 6
(page number not for citation purposes)
present study, FS decreased 55.2% over baseline (P  <
0.001); LVIDd and LVIDs increased markedly from 4.8 ±
1.2 mm and 1.5 ± 0.5 to 7.0 ± 1.1 mm and 4.8 ± 1.0 mm
respectively (P < 0.001). These results are consistent with
the findings by Oie et al. [22].
The mechanism of heart failure remains mostly unclear.
The loss of cardiomyocytes may play an important role in
causing heart failure [28]. Apoptosis is an important
source for cardiomyocyte loss. There were 38.92 apoptotic
cells per million myocardial cells in rats with heart failure,
whereas the rate was only 2.21 cells per million myocar-
dial cells in healthy rats [29].
A previous study showed that quinapril significantly sup-
pressed the incidence of apoptotic myocytes around the
necrotic region [30]. In the present study, quinapril signif-
icantly suppressed the incidence of apoptotic myocytes in
the CHF rats. It was demonstrated that cardiomyocyte
apoptosis and various genes associated with apoptosis
were inhibited in mice with myocarditis after Astragalo-
side treatment [12]. In the present study, apoptotic myo-
cytes significantly decreased in the CHF rats treated with
ASI in a dose-dependent manner.
Conclusion
The present study showed that ASI improved cardiac func-
tions, inhibited compensatory hypertrophy of myocardial
cells and lowered the number of apoptotic myocytes.
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Table 2: Effects of ASI on +dp/dt and -dp/dt
Group Dose (mg/kg/day) +dp/dt (mmHg/s) -dp/dt (mmHg/s)
Sham - 3454 ± 774 3706 ± 517
Model - 2216 ± 800+++ 1922 ± 672+++
ASI 0.1 2459 ± 524 (0.3679) 2362 ± 610 (0.0710)
ASI 0.3 2838 ± 420* (0.0246) 2699 ± 425** (0.0021)
ASI 1.0 3066 ± 630** (0.0027) 2776 ± 578***
Quinapril 1.0 2847 ± 251* (0.0228) 2601 ± 310** (0.0065)
Note: Values are mean ± SD in each group (n = 10). +++P < 0.001: statistical significance over the sham group (comparison of group means after 
ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001: statistical significance over the model group (comparison of group means after ANOVA). No 
significance between ASI (1.0 mg/kg/day) and Quinapril treatments. Exact P values are available in brackets.
Table 3: Effects of ASI on LV dimensions
After treatment
Group Dose (mg/kg/day) Normal Before treatment 1 week 2 weeks
Sham - 4.8 ± 1.0 5.2 ± 1.3 5.2 ± 0.7 5.2 ± 0.9
Model - 4.8 ± 1.2 (0.9549) 7.0 ± 1.1++ (0.0046) 7.5 ± 0.4+++ 7.1 ± 0.7+++
LVIDd (mm) ASI 0.1 5.0 ± 0.8 (0.6785) 6.9 ± 1.2 (0.9603) 6.9 ± 1.0 (0.1601) 6.5 ± 1.1 (0.1109)
ASI 0.3 4.5 ± 1.2 (0.5850) 6.2 ± 1.9 (0.1946) 6.7 ± 1.7 (0.0547) 6.0 ± 0.9** (0.0057)
ASI 1.0 4.7 ± 1.5 (0.7629) 6.4 ± 1.3 (0.3389) 6.5 ± 0.8* (0.0193) 6.0 ± 0.5**$ (0.0046)
Quinapril 1.0 5.1 ± 1.2 (0.6512) 6.6 ± 1.1 (0.5964) 6.7 ± 0.8 (0.0574) 6.7 ± 0.9 (0.3837)
Sham - 1.3 ± 0.4 1.6 ± 0.4 1.5 ± 0.3 1.8 ± 0.5
Model - 1.5 ± 0.5 (0.4268) 4.8 ± 1+++ 5.6 ± 0.8+++ 5.5 ± 0.8+++
LVIDs (mm) ASI 0.1 1.4 ± 0.3 (0.8811) 4.9 ± 0.9 (0.8356) 4.5 ± 0.9* (0.0112) 4.7 ± 0.9* (0.0447)
ASI 0.3 1.2 ± 0.4 (0.1827) 4.5 ± 1.6 (0.3955) 4.0 ± 1.6*** 4.3 ± 1.0** (0.0027)
ASI 1.0 1.4 ± 0.4 (0.6903) 4.4 ± 0.8 (0.3353) 3.7 ± 0.7*** 3.8 ± 1.0***$
Quinapril 1.0 1.6 ± 0.7 (0.5180) 4.6 ± 0.7 (0.6125) 3.9 ± 0.6*** 4.8 ± 0.8 (0.0595)
Note: Values are mean ± SD in each group (n = 10). ++P < 0.01, +++P < 0.001: statistical significance over the sham group (comparison of group 
means after ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001: statistical significance over the model group (comparison of group means after ANOVA). 
$P < 0.05: statistical significance between ASI (1.0 mg/kg/day) and Quinapril treatments (comparison of group means after ANOVA). Exact P values 
are available in brackets.Chinese Medicine 2009, 4:6 http://www.cmjournal.org/content/4/1/6
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Table 4: Effects of ASI on LVSP, LVEDP and wall stress
Group Dose (mg/kg/day) LVSP (mmHg) LVEDP (mmHg) Wall stress (g/cm2)
Sham - 111.8 ± 12.1 -0.7 ± 5.8 47.7 ± 17.6
Model - 88.5 ± 14.0+++ 13.9 ± 5.4+++ 125.9 ± 28.0+++
ASI 0.1 101.4 ± 18.5* (0.0367) 10.6 ± 3.6 (0.1629) 120.4 ± 31.9 (0.6563)
ASI 0.3 101.6 ± 9.0* (0.0340) 9.8 ± 5.3 (0.0848) 108.3 ± 24.5 (0.1613)
ASI 1.0 100.2 ± 8.4$$ (0.0571) 6.2 ± 4.2** (0.0018) 97.9 ± 29.8* (0.0283)
Quinapril 1.0 84.0 ± 15.5 (0.4566) 3.5 ± 6.3*** 95.1 ± 31.7* (0.0167)
Note: Values are mean ± SD in each group (n = 10). +++P < 0.001: statistical significance over the sham group (comparison of group means after 
ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001: statistical significance over the model group (comparison of group means after ANOVA). $$P < 0.01: 
statistical significance between ASI (1.0 mg/kg/day) and Quinapril treatments (comparison of group means after ANOVA). Exact P values are 
available in brackets.
Table 5: Effects of ASI on myocardial hypertrophy
Group Dose 
(mg/kg/day)
LA wt/TL 
(mg/mm)
LV wt/TL 
(mg/mm)
RA wt/TL 
(mg/mm)
RV wt/TL 
(mg/mm)
Tibial length 
(mm)
Body weight (g)
Sham - 1.3 ± 0.6 20.3 ± 3.1 1.8 ± 0.6 5.5 ± 1.5 37.25 ± 1.23 290.2 ± 23.2
Model - 2.8 ± 0.7+++ 24.9 ± 2.1+++ 2.6 ± 0.5+++ 8.1 ± 1.5+++ 38.20 ± 1.70 280.1 ± 24.3
- - (0.1879) (0.3439)
ASI 0.1 2.4 ± 0.4 22.7 ± 2.8 2.5 ± 0.4 7.1 ± 1.0 38.96 ± 1.28 271.2 ± 18.0
(0.1855) (0.0862) (0.6751) (0.1031) (0.2723) (0.4038)
ASI 0.3 2.5 ± 0.7 22.6 ± 4.0 2.5 ± 0.5 7.1 ± 1.2 37.23 ± 1.36 287.9 ± 31.6
(0.2280) (0.0796) (0.7632) (0.099) (0.1811) (0.4639)
ASI 1.0 2.1 ± 0.6* 21.0 ± 2.6** 2.0 ± 0.7* 6.1 ± 1.3** 37.89 ± 1.28 294.5 ± 15.7
(0.015) (0.0031) (0.0186) (0.0017) (0.6827) (0.1794)
Quinapril 1.0 2.0 ± 0.8** 22.0 ± 1.8* 2.0 ± 0.6* 7.2 ± 1.8 38.13 ± 2.27 280.1 ± 25.6
(0.0076) (0.0255) (0.0223) (0.1485) (0.9434) (1.0)
Note: Values are mean ± SD in each group (n = 10). +++P < 0.001: statistical significance over the sham group (comparison of group means after 
ANOVA). *P < 0.05, **P < 0.01: statistical significance over the model group (comparison of group means after ANOVA). No statistical significance 
between ASI (1.0 mg/kg/day) and Quinapril treatments (comparison of group means after ANOVA). Exact P values are available in brackets.
Table 6: Effects of ASI on myocardial apoptosis and Bax
Group Dose (mg/kg/day) Apoptotic cell Bax protein
Sham - 3.0 ± 2.2 1.6 ± 1.3
Model - 54.0 ± 10.2+++ 30.2 ± 8.8+++
ASI 0.1 37.8 ± 8.6*** 24.3 ± 7.1*
ASI 0.3 17.0 ± 8.4*** 8.4 ± 5.3***
ASI 1.0 8.0 ± 5.6*** 7.3 ± 3.4***
Quinapril 1.0 10.4 ± 6.4*** 12.0 ± 5.5***
Note: Values are mean ± SD in each group (n = 10). +++P < 0.001: statistical significance over the sham group (comparison of group means after 
ANOVA). *P < 0.05, ***P < 0.001: statistical significance over the model group (comparison of group means after ANOVA). No statistical 
significance between ASI (1.0 mg/kg/day) and Quinapril treatments (comparison of group means after ANOVA).Publish with BioMed Central    and   every 
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